Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.

Biomea Fusion shares are trading lower after the company announced the termination of its proposed public offering of securities.

Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions

Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously

8-K filing — Decoy Therapeutics Inc. (DCOY)

Filed: 2026-09-23 AccNo: 0001615219-26-000019 Size: 593 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results

U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.

Decoy Therapeutics To Exercise 1,184,434 Series B Warrants At $3.25/Share for ~$3.85M; Cuts Series A & C Warrant Prices To $3.25 And Issues 2,368,868 New Warrants At $3.25/Share

Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral